Autopsy report · NCT04590664

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“PI Decision”

The sponsor’s own words in the registry.

Life of this trial

Registered 3 months before it started.
Ran for about 4 years 1 month before it stopped.
9 participants enrolled.
Results were posted on the registry 1 year 8 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: Emory University
Sponsor type: University, hospital or other
Conditions: Glioblastoma; Recurrent Glioblastoma
Interventions: Verteporfin
Participants: 9
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.